Publications by authors named "Rodrigo Holanda Mendonca"

Background:  Spinal muscular atrophy linked to chromosome 5q (SMA-5q) is a neurodegenerative disorder caused by mutations in the gene.

Objective:  To describe the key demographic, clinical and genetic characteristics, as well as natural history data of patients with SMA-5q.

Methods:  Up to January 2022, 706 patients with confirmed genetic diagnosis of SMA-5q, or their parents, completed a self-reported questionnaire on natural history, genetic characteristics, drug treatments, and multidisciplinary care.

View Article and Find Full Text PDF

In recent years, significant progress has been made in 5q Spinal Muscular Atrophy therapeutics, emphasizing the importance of early diagnosis and intervention for better clinical outcomes. Characterized by spinal cord motor neuron degeneration, 5q-SMA leads to muscle weakness, swallowing difficulties, respiratory insufficiency, and skeletal deformities. Recognizing the pre-symptomatic phases supported by screening and confirmatory genetic tests is crucial for early diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • Spinal muscular atrophy (SMA) is a severe neuromuscular disorder leading to muscle weakness and reduced life expectancy, with onasemnogene abeparvovec being the first approved gene therapy for it.
  • A study involving 41 SMA patients (mostly type 1) showed significant motor function improvement after gene therapy, with nearly half of the type 1 patients gaining the ability to sit independently.
  • Adverse effects were common, including liver enzyme elevation in 70.7% of patients and thrombocytopenia in 31.7%, while the presence of previous nusinersen treatment didn't further enhance motor function post-gene therapy.
View Article and Find Full Text PDF

Spinal muscular atrophy linked to chromosome 5 (SMA-5q) is an autosomal recessive genetic disease caused by mutations in the . SMA-5q is characterized by progressive degeneration of the spinal cord and bulbar motor neurons, causing severe motor and respiratory impairment with reduced survival, especially in its more severe clinical forms. In recent years, highly effective disease-modifying therapies have emerged, either acting by regulating the splicing of exon 7 of the gene or adding a copy of the gene through gene therapy, providing a drastic change in the natural history of the disease.

View Article and Find Full Text PDF

Objective: We investigated ultrasound patterns of muscle involvement in different types of spinal muscular atrophy (SMA) and their correlation with functional status to determine the pattern of muscle compromise in patients with SMA and the potential role of ultrasound to evaluate disease progression.

Methods: We examined muscles (biceps brachii, rectus femoris, diaphragm, intercostals and thoracic multifidus) of 41 patients with SMA (types 1 to 4) and 46 healthy age- and sex-matched control individuals using B-mode ultrasound for gray-scale analysis (GSA), area (biceps brachii and rectus femoris) and diaphragm thickening ratio. Functional scales were applied to patients only.

View Article and Find Full Text PDF
Article Synopsis
  • Monogenic neuromuscular disorders can potentially be treated with gene therapy using viral vectors to restore protein function or silence harmful genes.
  • Spinal Muscular Atrophy (SMA) serves as a key example, with an AAV9-based gene therapy called AVXS-101 already approved for treatment.
  • The review will cover different types of viral vectors, their mechanisms, and the clinical trials that led to the approval of gene therapy for SMA and other treatable neuromuscular diseases.
View Article and Find Full Text PDF

Background: The COVID-19 pandemic has brought substantial challenges for current practices in treating hereditary neuromuscular disorders (hNMDs). However, this infection has not been the only concern for these patients. Social distancing has compromised multidisciplinary assistance and physical activity, and has brought about several mental health issues.

View Article and Find Full Text PDF

A 34-year-old man presented with a history of 21-days of gait unsteadiness and diplopia. Ten days before presentation, he developed limb weakness and in the last three days reduced consciousness. HIV infection was diagnosed three months ago (CD4+ = 160 cells/mm; viral load HIV-1 = 144.

View Article and Find Full Text PDF

Spinal muscular atrophy (SMA) is a motor neuron disease associated with progressive muscle weakness and motor disability. The motor unit number index (MUNIX) is a biomarker used to assess loss of motor units in later-onset SMA patients. Twenty SMA patients (SMA types 3 and 4), aged between 7 and 41 years, were clinically evaluated through the Hammersmith Motor Functional Scale Expanded and the Spinal Muscular Atrophy-Functional Rating Scale.

View Article and Find Full Text PDF

BackgroundSpinal muscular atrophy type 1 (SMA1) is a motor neuron disease associated with progressive muscle weakness, ventilatory failure, and reduced survival.Objective:To report the evaluation of the nusinersen, an antisense oligonucleotide, on the motor function of SMA1.MethodsThis was a longitudinal and observational study to assess the outcomes of nusinersen therapy in SMA1 patients using the HINE-2 and CHOP-INTEND scales.

View Article and Find Full Text PDF

Background: More than one-third of COVID-19 patients present neurological symptoms ranging from anosmia to stroke and encephalopathy. Furthermore, pre-existing neurological conditions may require special treatment and may be associated with worse outcomes. Notwithstanding, the role of neurologists in COVID-19 is probably underrecognized.

View Article and Find Full Text PDF

The most common causes of congenital myasthenic syndromes (CMS) are CHRNE mutations, and some pathogenic allelic variants in this gene are especially frequent in certain ethnic groups. In the southern region of Brazil, a study found the c.130dupG CHRNE mutation in up to 33% of families with CMS.

View Article and Find Full Text PDF